Clh Report for 2,4-Dinitrophenol
Total Page:16
File Type:pdf, Size:1020Kb
CLH report Proposal for Harmonised Classification and Labelling Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2 Substance Name: 2,4-Dinitrophenol EC Number: 200-087-7 CAS Number: 51-28-5 Index Number: 609-041-00-4 Contact details for dossier submitter: Federal Institute for Occupational Safety and Health (BAuA) Federal Office for Chemicals Friedrich-Henkel-Weg 1-25 D-44149 Dortmund, Germany [email protected] Version number: 1.0 Date: November 2017 CLH REPORT FOR 2,4-DINITROPHENOL CONTENTS Part A. 1 PROPOSAL FOR HARMONISED CLASSIFICATION AND LABELLING ................................................. 4 1.1 SUBSTANCE ........................................................................................................................................................... 4 1.2 HARMONISED CLASSIFICATION AND LABELLING PROPOSAL .................................................................................. 4 1.3 PROPOSED HARMONISED CLASSIFICATION AND LABELLING BASED ON CLP REGULATION .................................... 5 2 BACKGROUND TO THE CLH PROPOSAL ..................................................................................................... 7 2.1 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING .............................................................................. 7 2.2 SHORT SUMMARY OF THE SCIENTIFIC JUSTIFICATION FOR THE CLH PROPOSAL .................................................... 7 2.3 CURRENT HARMONISED CLASSIFICATION AND LABELLING .................................................................................... 7 2.3.1 Current classification and labelling in Annex VI, Table 3.1 in the CLP Regulation .................................. 7 2.4 CURRENT SELF-CLASSIFICATION AND LABELLING ................................................................................................. 7 2.4.1 Current self-classification and labelling based on the CLP Regulation criteria ........................................ 7 3 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL ................................................ 8 Part B. 1 IDENTITY OF THE SUBSTANCE ...................................................................................................................... 9 1.1 NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE .............................................................................................. 9 1.2 COMPOSITION OF THE SUBSTANCE ...................................................................................................................... 10 1.2.1 Composition of test material ..................................................................................................................... 10 1.3 PHYSICO-CHEMICAL PROPERTIES ........................................................................................................................ 10 4 HUMAN HEALTH HAZARD ASSESSMENT .................................................................................................. 13 4.1 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION) ............................................. 13 4.1.1 Non-human information ............................................................................................................................ 13 4.1.2 Human information ................................................................................................................................... 16 4.1.3 Summary and discussion on toxicokinetics ............................................................................................... 19 4.2 ACUTE TOXICITY ................................................................................................................................................. 20 4.2.1 Non-human information ............................................................................................................................ 20 4.2.1.1 Acute toxicity: oral ................................................................................................................................................ 20 4.2.1.2 Acute toxicity: inhalation ....................................................................................................................................... 23 4.2.1.3 Acute toxicity: dermal ............................................................................................................................................ 23 4.2.1.4 Acute toxicity: other routes .................................................................................................................................... 24 4.2.2 Human information ................................................................................................................................... 24 4.2.3 Summary and discussion of acute toxicity ................................................................................................ 27 4.2.4 Comparison with criteria .......................................................................................................................... 28 4.2.5 Conclusions on classification and labelling ............................................................................................. 29 4.7 REPEATED DOSE TOXICITY .................................................................................................................................. 29 4.7.1 Non-human information ............................................................................................................................ 29 4.7.1.1 Repeated dose toxicity: oral ................................................................................................................................... 29 4.7.1.2 Repeated dose toxicity: inhalation ......................................................................................................................... 30 4.7.1.3 Repeated dose toxicity: dermal .............................................................................................................................. 30 4.7.1.4 Repeated dose toxicity: other routes ...................................................................................................................... 30 4.7.1.5 Human information ................................................................................................................................................ 30 4.7.1.6 Other relevant information ..................................................................................................................................... 30 4.7.1.7 Summary and discussion of repeated dose toxicity ................................................................................................ 30 4.8 SPECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) ............................ 30 4.8.1 Summary and discussion of repeated dose toxicity findings relevant for classification as STOT RE according to CLP Regulation .................................................................................................................................. 31 4.8.2 Comparison with criteria of repeated dose toxicity findings relevant for classification as STOT RE ...... 31 4.8.3 Conclusions on classification and labelling of repeated dose toxicity findings relevant for classification as STOT RE ............................................................................................................................................................. 31 7 REFERENCES ...................................................................................................................................................... 32 2 CLH REPORT FOR 2,4-DINITROPHENOL Tables Table 1: Substance identity ............................................................................................................................................ 4 Table 2: The current Annex VI entry and the proposed harmonised classification ....................................................... 4 Table 3: Proposed classification according to the CLP Regulation ............................................................................... 5 Table 4: Self-classification by the registrant (on March, 22nd, 2017) ............................................................................ 7 Table 5: Substance identity ............................................................................................................................................ 9 Table 6: Constituents (non-confidential information) .................................................................................................. 10 Table 7: Impurities (non-confidential information) ..................................................................................................... 10 Table 8: Additives (non-confidential information) ...................................................................................................... 10 Table 9: Summary of physico - chemical properties ................................................................................................... 10 Table 10: Summary table of relevant acute oral toxicity studies .............................................................................. 20 Table 11: Acute oral toxicity of dinitrophenol (Spencer et al., 1948) ....................................................................... 21 Table 12: Summary table of relevant acute dermal toxicity studies.......................................................................... 23 Table 13: Fatal oral poisonings with information about doses